Annals of Surgical Oncology

, Volume 26, Issue 3, pp 829–835 | Cite as

The Therapeutic Survival Benefit of Splenic Hilar Nodal Dissection for Advanced Proximal Gastric Cancer Invading the Greater Curvature

  • Masahiro Yura
  • Takaki YoshikawaEmail author
  • Sho Otsuki
  • Yukinori Yamagata
  • Shinji Morita
  • Hitoshi Katai
  • Toshirou Nishida
Gastrointestinal Oncology



The Japan Clinical Oncology Group phase 3 study confirmed the survival non-inferiority of spleen-preserving surgery against splenectomy for advanced proximal gastric cancer not invading the greater curvature. However, the efficacy of #10 lymph node (LN) dissection for tumors that involve the greater curvature remains unclear.


Data from patients who underwent D2-total gastrectomy with splenectomy between January 2000 and December 2012 were retrospectively reviewed. The study included 593 patients. The patients were split into two groups, with 212 patients in the tumor invasion of the greater curvature (Gre) group and 381 patients in the non-Gre group. Survival curves and the state of LN metastasis and the index of estimated benefit from LN dissection of each station were evaluated.


The incidence of #10 LN metastasis was 8.1% (48/593): 15.1% in the Gre group and 4.2% in the non-Gre group. The 5-year overall survival rates for the patients with and without #10 metastasis were respectively 46.9 and 50.2% (P = 0.829) in the Gre group and 49.6 and 62.3% (P = 0.074) in the non-Gre group. The indices for #10 LN dissection were 7.1 in the Gre group and 2.3 in the non-Gre group. In the Gre group, the node station with the highest index was #3, followed by #4d, #1, #4sb, #4sa, #7, #2, #10 (index > 7).


The splenic hilar nodes should be prioritized as a component of D2 lymphadenectomy for advanced gastric cancer invading the greater curvature based on its high metastatic rate and index.



The authors declares that they have no conflict of interest.


  1. 1.
    Association JGC. Japanese classification of gastric carcinoma. 15th ed. Kanehara Publisher, Tokyo, 2017.Google Scholar
  2. 2.
    Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer. 1999;79:1522–30.CrossRefGoogle Scholar
  3. 3.
    Sano T, Sasako M, Mizusawa J, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg. 2017;265:277–83.CrossRefGoogle Scholar
  4. 4.
    Maezawa Y, Aoyama T, Yamada T, et al. Priority of lymph node dissection for proximal gastric cancer invading the greater curvature. Gastric Cancer. 2018;21:569–72.CrossRefGoogle Scholar
  5. 5.
    Watanabe M, Kinoshita T, Enomoto N, Shibasaki H, Nishida T. Clinical significance of splenic hilar dissection with splenectomy in advanced proximal gastric cancer: an analysis at a single institution in Japan. World J Surg. 2016;40:1165–71.CrossRefGoogle Scholar
  6. 6.
    Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1–19.CrossRefGoogle Scholar
  7. 7.
    Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Kuniyoshi Arai, for the ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Eng J Med. 2007;357:1810–20.Google Scholar
  8. 8.
    Control UfIC. TNM Classification of Malignant Tumors. 8th ed. London: Wiley; 2017.Google Scholar
  9. 9.
    Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surgev. 1995;82:346–51.CrossRefGoogle Scholar
  10. 10.
    Ikeguchi M, Kaibara N. Lymph node metastasis at the splenic hilum in proximal gastric cancer. Am Surg. 2004;70:645–8.Google Scholar
  11. 11.
    Aoyagi K, Kouhuji K, Miyagi M, Imaizumi T, Kizaki J, Shirouzu K. Prognosis of metastatic splenic hilum lymph node in patients with gastric cancer after total gastrectomy and splenectomy. World J Hepatol. 2010;2:81–6.CrossRefGoogle Scholar
  12. 12.
    Bonenkamp JJ, Songun I, Welvaart K, van de Velde CJH, Hermans J, Sasako M, Plukker JTM, van Elk P, Obertop H, Gouma DJ, Taat CW, van Lanschot J, Meyer S, de Graaf PW, von Meyenfeldt MF, Tilanus, H. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345:745–8.CrossRefGoogle Scholar
  13. 13.
    Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996;13:995–9.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Masahiro Yura
    • 1
  • Takaki Yoshikawa
    • 1
    Email author
  • Sho Otsuki
    • 1
  • Yukinori Yamagata
    • 1
  • Shinji Morita
    • 1
  • Hitoshi Katai
    • 1
  • Toshirou Nishida
    • 1
  1. 1.Department of Gastric SurgeryNational Cancer Center HospitalTokyoJapan

Personalised recommendations